title: Oral etoposide for platinum-resistant and recurrent epithelial ovarian cancer: a study by the Anatolian Society of Medical Oncology.
abstract: BACKGROUND
  The aim of this study was to evaluate the efficacy and toxicity of long-term, low-dose oral etoposide as an advanced treatment option in patients with platinum resistant epithelial ovarian cancer.
  
  
  METHODS
  For the purposes of this study, 51 patients with histologically-confirmed, recurrent or metastatic platinum-resistant epithelial ovarian cancer (EOC) treated at six different centers between January 2006 and January 2011 were retrospectively evaluated. Patients were treated with oral etoposide (50 mg/day for a cycle of 14 days, repeated every 21 days).
  
  
  RESULTS
  Among the 51 platinum-resistant patients, 17.6% demonstrated a partial response and 25.5% a stable response. The median progression-free survival (PFS) was 3.9 months (95% CI, 2.1-5.7), while the median overall survival was 16.4 months (11.8-20.9). No significant relationship was observed between the pre-treatment CA 125 levels, post-treatment CA-125 levels and the treatment response rates (p=0.21). Among the 51 patients who were evaluated in terms of toxicity, grade 1 or 4 hematologic toxicity was observed in 19 (37.3%); and grade 1-4 gastrointestinal toxicity occurred in 15 patients (29.4%).
  
  
  CONCLUSIONS
  Chronic low-dose oral etoposide treatment is generally effective and well-tolerated in platinum-resistant ovarian cancer patients.
authors.affiliation: Department of Medical Oncology, Dicle University, Diyarbakir, Turkey. drmehmetonko@hotmail.com
authors.forename: Mehmet
authors.initials: M
authors.lastname: Kucukoner
authors.forename: Abdurrahman
authors.initials: A
authors.lastname: Isikdogan
authors.forename: Sebnem
authors.initials: S
authors.lastname: Yaman
authors.forename: Ozge
authors.initials: O
authors.lastname: Gumusay
authors.forename: Olcun
authors.initials: O
authors.lastname: Unal
authors.forename: Arife
authors.initials: A
authors.lastname: Ulas
authors.forename: Emir T
authors.initials: ET
authors.lastname: Elkiran
authors.forename: Muhammed A
authors.initials: MA
authors.lastname: Kaplan
authors.forename: Nuriye
authors.initials: N
authors.lastname: Ozdemir
authors.forename: Ali
authors.initials: A
authors.lastname: Inal
authors.forename: Zuhat
authors.initials: Z
authors.lastname: Urakci
authors.forename: Suleyman
authors.initials: S
authors.lastname: Buyukberber
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D000077216:Carcinoma, Ovarian Epithelial; D005047:Etoposide / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008495:Medical Oncology; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D010984:Platinum / Q000627:therapeutic use*; D011379:Prognosis; D012189:Retrospective Studies; D016879:Salvage Therapy; D015996:Survival Rate
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D010984:Platinum; D005047:Etoposide